09.05.24
Pfizer has appointed Elif Aral as Regional President for Middle East, Russia, and Africa (MERA) to spearhead operations in the region for vaccines, oncology, rare diseases, internal medicine, hospitals, and inflammation and immunology.
In her new role, in addition to overseeing all therapeutic areas within the MERA region, Aral will drive strategic initiatives aimed at improving healthcare access, working closely with regional partners and governments.
Prior to leading Accord, Aral worked as the CV Metabolic and Global Brands Lead in Internal Medicine where she was responsible for overseeing a portfolio of over 200 medicines, working globally to enhance performance and ensure the supply of crucial medications to patients. She also served as the Vaccines Lead for Emerging Markets, managing a $1.4 billion portfolio.
"As I take on this new role, my foremost goal is to build upon the strong foundation we have established across the MERA region over the past 70 years,” said Aral. “I am deeply committed to ensuring that our global innovative treatments and breakthrough therapies are not only developed but also made accessible as we continue to bridge the healthcare equity gap, working together with our dedicated teams and partners to drive meaningful change and improve health outcomes for communities across the region."
In her new role, in addition to overseeing all therapeutic areas within the MERA region, Aral will drive strategic initiatives aimed at improving healthcare access, working closely with regional partners and governments.
Experience
Aral began her journey with Pfizer in 1995, with a career marked by significant achievements. Most recently, she led Pfizer's 'An Accord for a Healthier World' initiative, where she collaborated with cross-functional teams to provide current and future Pfizer medicines and vaccines on a not-for-profit basis in 45 lower-income countries. The initiative aims to reduce the health equity gap by ensuring affordable access to essential medications and addressing systemic barriers that hinder patient access to healthcare.Prior to leading Accord, Aral worked as the CV Metabolic and Global Brands Lead in Internal Medicine where she was responsible for overseeing a portfolio of over 200 medicines, working globally to enhance performance and ensure the supply of crucial medications to patients. She also served as the Vaccines Lead for Emerging Markets, managing a $1.4 billion portfolio.
"As I take on this new role, my foremost goal is to build upon the strong foundation we have established across the MERA region over the past 70 years,” said Aral. “I am deeply committed to ensuring that our global innovative treatments and breakthrough therapies are not only developed but also made accessible as we continue to bridge the healthcare equity gap, working together with our dedicated teams and partners to drive meaningful change and improve health outcomes for communities across the region."
